Download PDF
Thromb Haemost 1978; 40(02): 532-541
DOI: 10.1055/s-0038-1648686
Original Article
Schattauer GmbH Stuttgart

Natural Oestrogen in the Female Climacteric - Influence on Blood Coagulation and Fibrinolysis

Anders Lagrelius
The Departments of Obstetrics and Gynecology, Huddinge Hospital, and Blood Coagulation Disorders, Karolinska Hospital, Stockholm, Sweden
,
Nils-Olov Lunell
The Departments of Obstetrics and Gynecology, Huddinge Hospital, and Blood Coagulation Disorders, Karolinska Hospital, Stockholm, Sweden
,
Margareta Blombäck
The Departments of Obstetrics and Gynecology, Huddinge Hospital, and Blood Coagulation Disorders, Karolinska Hospital, Stockholm, Sweden
› Author Affiliations
Further Information

Publication History

Received 26 October 1977

Accepted 27 March 1978

Publication Date:
12 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

The aim of the present study was to investigate the effect on blood coagulation and fibrinolysis of a natural oestrogen preparation, piperazine oestrone sulphate, prospectively in menopausal women. Scopolamine was given to the control group.

The women were investigated before and during treatment with regard to factors VIII, VII, X, V, fibrinopeptide A, antithrombin III, plasminogen, rapid antiplasmin and α1-antitrypsin. There was no significant change towards hypercoagulability or decreased fibrinolysis in any group. In the oestrogen group, however, a tendency towards an increased level of plasminogen and a decreased level of antiplasmin was demonstrated. In the scopolamine group there was an unexpected fall in factors X and V and also in plasminogen and α1,-antitrypsin. A low level of some blood coagulation factors in some of the women before treatment is somewhat astonishing; none of them had any history of excessive bleeding.

 

  • References

  • 1 Abildgaard U, Lie M, ØDegård OR. 1976; A simple amidolytic method for the determination of functionally active antithrombin III. Scandinavian Journal of Clinical and Laboratory Investigation 36: 109
    CrossrefPubMedGoogle Scholar
  • 2 Alkjaersig N, Fletcher A, Burstein R. 1975; Association between oral contraceptive use and thromboembolism: A new approach to its investigation based on plasma fibrinogen chromatography. American Journal of Obstetrics and Gynecology 122: 199
    CrossrefPubMedGoogle Scholar
  • 3 Åstedt B. 1971; Low fibrinolytic activity of veins during treatment with ethinyl oestradiol. Acta Obstetricia et Gynecologica Scandinavica 50: 279
    CrossrefPubMedGoogle Scholar
  • 4 Aylward M, Maddock J, Rees P. 1976; Natural oestrogen replacement therapy and blood clotting. British Medical Journal 1: 220
    PubMedGoogle Scholar
  • 5 Bachmann F, Duckert F, Roller F. 1958; The Stuart-Prower factor assay and its clinical significance. Thrombosis et Diathesis Haemorrhagica 2: 24
    PubMedGoogle Scholar
  • 6 Brakman P. 1968. In: Astrup T, Wright IS. (ed.) Blood coagulation, thrombosis and female hormones. James F Mitchell Foundation; Washington: p 27
    Google Scholar
  • 7 Blombäck M, Blombäck B, Holmqvist H. 1976; Immunological characterization of early fibrinogen degradation products. Radioimmunoassay of fragments released from the Aa-chain of fibrinogen Thrombosis Research 8: 567
    CrossrefPubMedGoogle Scholar
  • 8 Collen D, De Cock F, Verstraete M. 1975; Immunochemical distinction between antiplasmin and α1-antitrypsin. Thrombosis Research 7: 245
    CrossrefPubMedGoogle Scholar
  • 9 Coope J, Thomson JM, Poller L. 1975; Effects of “natural oestrogen” replacement therapy on menopausal symptoms and blood clotting. British Medical Journal 4: 139
    CrossrefPubMedGoogle Scholar
  • 10 Fagerhol MK, Abildgaard U. 1970; Immunological studies on human antithrombin III. Scandinavian Journal of Haematology 7: 10
    PubMedGoogle Scholar
  • 11 Gjønaess H, Fagerhol MK. 1974; Studies on plasma coagulation and fibrinolysis during oral contraception of various types. Scandinavian Journal of Haematology 12: 232
    PubMedGoogle Scholar
  • 12 Hedlin AM. 1975; The effect of oral contraceptive Estrogen on blood coagulation and fibrinolysis. Thrombosis Diathesis et Haemorrhagica 33: 370
    PubMedGoogle Scholar
  • 13 Holmberg L, Nilsson IM. 1974; AHF related protein in clinical praxis. Scandinavian Journal of Haematology 12: 221
    PubMedGoogle Scholar
  • 14 Howie PW, Mallinson AC, Prentice CR M, Horne CH W, McNicol GP. 1970; Effect of combined oestrogen-progestogen oral contraceptives, oestrogen and progestogen on antiplasmin and antithrombin activity. The Lancet 2: 1329
    PubMedGoogle Scholar
  • 15 Kappeler R. 1955; Das Verhalten von Faktor V im Serum unter normalen und pathologischen Bedingungen. Zeitschrift fur klinische Medizin 153: 103
    PubMedGoogle Scholar
  • 16 Von Kaulla KN. 1976; Oestrogens and blood coagulation. Triangle 15: 9
    PubMedGoogle Scholar
  • 17 Kockum C. 1976; Radioimmunoassay of fibrinopeptide A - clinical application. Thrombosis Research 8: 225
    CrossrefPubMedGoogle Scholar
  • 18 Roller F, Loeliger A, Duckert F. 1951; Experiments on a new clotting factor(factor VII). Acta Haematologica 6: 1
    CrossrefPubMedGoogle Scholar
  • 19 Laurell C-B. 1966; Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Analytical Biochemistry 15: 45
    CrossrefPubMedGoogle Scholar
  • 20 Mancini G, Carbonara A, Heremans JF. 1965; Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry 2: 235
    CrossrefPubMedGoogle Scholar
  • 21 Matsuda T. Coagulability of blood and fibrinolysis related to age and lipids. In: Vth Congress of the International Society of Thrombosis and Haemostasis; Paris: 07/1975. abstr 531
    Google Scholar
  • 22 Nilsson IM, Blombäck M, Thilen A, Von Francken I. 1959; Carriers of hemophilia A. A laboratory study Acta Medica Scandinavica 165: 357
    PubMedGoogle Scholar
  • 23 Meade TW, Brosovic M, Chakrabarti R, Howarth DJ, North WR S, Stirling Y. 1976; An epidemiological study of the haemostatic and other effects of oral contraceptives. British Journal of Haematology 34: 353
    CrossrefPubMedGoogle Scholar
  • 24 Müllertz S. 1974; Different molecular forms of plasminogen and plasmin produced by urokinase in human plasma and their relation to protease inhibitors and lysis of fibrinogen and fibrin. Biochemical Journal 143: 273
    CrossrefPubMedGoogle Scholar
  • 25 Nilsson IM, Blombäck M, Von Francken I. 1957; On an inherited autosomal hemorrhagic diathesis with antihemophilic globulin(AHG) deficiency and prolonged bleeding time. Acta Medica Scandinavica 159: 35
    PubMedGoogle Scholar
  • 26 Nossel HL, Yudelman I, Canfield RE, Butler Jr VP, Spanondis R, Wilner GD, Qureshi GD. 1974; Measurement of fibrinopeptide A in human blood. Journal of Clinical Investigation 54: 43
    CrossrefPubMedGoogle Scholar
  • 27 ØDegård OR, Lie M, Abildgaard U. 1975. Heparin co-factor activity measured with an amidolytic method. Thrombosis Research, 6, 287 as modified by Ødegård in 1976(personal communication);
    Google Scholar
  • 28 Poller L, Thomson JM. 1966; Clotting factors during oral contraception: further report. British Medical Journal 2: 23
    CrossrefPubMedGoogle Scholar
  • 29 Shanberge JN, Tanaka K, Gruhl MC, Ikemori R, Inoshita K. 1972; The effect of oral contraceptives on fibrin-clot stabilization. New York Academy of Science 202: 220
    CrossrefPubMedGoogle Scholar
  • 30 Stern MD, Givner ML. Studies on the mechanism of action of conjugated equine oestrogens. Symposium held at Charing Cross Medical School Hospital 11/1976
    PubMedGoogle Scholar
  • 31 Teger-Nilsson AC, Friberger P, Gyzander E. 1977 Determination of a new rapid plasmin inhibitor in human blood by means of a plasmin specific tripeptide substrate. >Scandinavian Journal of Clinical & Laboratory Investigation. To be published
    PubMedGoogle Scholar
  • 32 Vermylen C, De Vreeker RA, Verstraete M. 1963; A rapid enzymatic method for assay of fibrinogen fibrin polymerization time(FPT test). Clinica Chimica Acta 8: 418
    CrossrefPubMedGoogle Scholar